BACKGROUND:ASA404 (5,6-dimethylxanthenone-4-acetic acid) is a small-molecule, flavonoid tumor-vascular disrupting agent. Pooled data from phase II studies were analyzed retrospectively to compare safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients. METHODS: Data from previously untreated patients with stage IIIb/IV NSCLC who were randomized to receive up to six cycles of carboplatin (C; AUC 6 mg/ml•min) and paclitaxel (P; 175 mg/m(2)) alone or with ASA404 (1200 mg/m(2)), or enrolled in an extension study to receive CP and ASA404 (1800 mg/m(2)), were analyzed. Differences between subgroups were calculated using Fisher's exact test. RESULTS: Of the 108 enrolled patients, safety data from the 104 patients included in the safety population were pooled to compare results between histological subgroups (squamous vs non-squamous) and treatment (CP alone vs CP + ASA404). Addition of ASA404 to the standard chemotherapy regimen did not appear to substantially increase toxicity, and there were no serious adverse events associated with bleeding, pulmonary hemorrhage, or hemoptysis. Activity with CP + ASA404 appeared improved over CP alone, with median survival 10.2 vs 5.5 months in squamous, and 14.9 vs 11.0 months in non-squamous populations, respectively. CONCLUSION: This analysis is limited by its retrospective nature, and by the small size of the overall group, treatment and disease subgroups. However, as ASA404 appears to have a similar safety and activity profile in patients with squamous and non-squamous NSCLC, the findings support inclusion of both groups of patients in ongoing definitive phase III trials of ASA404 (NCT00832494).
RCT Entities:
BACKGROUND:ASA404 (5,6-dimethylxanthenone-4-acetic acid) is a small-molecule, flavonoid tumor-vascular disrupting agent. Pooled data from phase II studies were analyzed retrospectively to compare safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients. METHODS: Data from previously untreated patients with stage IIIb/IV NSCLC who were randomized to receive up to six cycles of carboplatin (C; AUC 6 mg/ml•min) and paclitaxel (P; 175 mg/m(2)) alone or with ASA404 (1200 mg/m(2)), or enrolled in an extension study to receive CP and ASA404 (1800 mg/m(2)), were analyzed. Differences between subgroups were calculated using Fisher's exact test. RESULTS: Of the 108 enrolled patients, safety data from the 104 patients included in the safety population were pooled to compare results between histological subgroups (squamous vs non-squamous) and treatment (CP alone vs CP + ASA404). Addition of ASA404 to the standard chemotherapy regimen did not appear to substantially increase toxicity, and there were no serious adverse events associated with bleeding, pulmonary hemorrhage, or hemoptysis. Activity with CP + ASA404 appeared improved over CP alone, with median survival 10.2 vs 5.5 months in squamous, and 14.9 vs 11.0 months in non-squamous populations, respectively. CONCLUSION: This analysis is limited by its retrospective nature, and by the small size of the overall group, treatment and disease subgroups. However, as ASA404 appears to have a similar safety and activity profile in patients with squamous and non-squamous NSCLC, the findings support inclusion of both groups of patients in ongoing definitive phase III trials of ASA404 (NCT00832494).
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Mark J McKeage; Martin Reck; Michael B Jameson; Mark A Rosenthal; David Gibbs; Paul N Mainwaring; Lutz Freitag; Richard Sullivan; Joachim Von Pawel Journal: Lung Cancer Date: 2009-05-05 Impact factor: 5.705
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: M J McKeage; J Von Pawel; M Reck; M B Jameson; M A Rosenthal; R Sullivan; D Gibbs; P N Mainwaring; M Serke; J-J Lafitte; C Chouaid; L Freitag; E Quoix Journal: Br J Cancer Date: 2008-12-16 Impact factor: 7.640
Authors: Wei Liu; Gloria B Kim; Nathan A Krump; Yuqi Zhou; James L Riley; Jianxin You Journal: Proc Natl Acad Sci U S A Date: 2020-06-01 Impact factor: 11.205